These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 23434145)

  • 1. Molecular markers of therapeutic resistance in breast cancer.
    Zhou L; Luo Y; Li K; Tian L; Wang M; Li C; Huang Q
    Hum Pathol; 2013 Jul; 44(7):1421-8. PubMed ID: 23434145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel prognostic markers for patients with triple-negative breast cancer.
    Zhou L; Li K; Luo Y; Tian L; Wang M; Li C; Huang Q
    Hum Pathol; 2013 Oct; 44(10):2180-7. PubMed ID: 23845466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The mRNA expression of inhibitors of DNA binding-1 and -2 is associated with advanced tumour stage and adverse clinical outcome in human breast cancer.
    Wazir U; Jiang WG; Sharma AK; Newbold RF; Mokbel K
    Anticancer Res; 2013 May; 33(5):2179-83. PubMed ID: 23645773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nuclear localization of GLI1 and elevated expression of FOXC2 in breast cancer is associated with the basal-like phenotype.
    Li Y; Yang W; Yang Q; Zhou S
    Histol Histopathol; 2012 Apr; 27(4):475-84. PubMed ID: 22374725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
    Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased claudin-4 expression is associated with poor prognosis and high tumour grade in breast cancer.
    Lanigan F; McKiernan E; Brennan DJ; Hegarty S; Millikan RC; McBryan J; Jirstrom K; Landberg G; Martin F; Duffy MJ; Gallagher WM
    Int J Cancer; 2009 May; 124(9):2088-97. PubMed ID: 19142967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coordinate expression of apoptosis-associated proteins in human breast cancer before and during chemotherapy.
    Parton M; Krajewski S; Smith I; Krajewska M; Archer C; Naito M; Ahern R; Reed J; Dowsett M
    Clin Cancer Res; 2002 Jul; 8(7):2100-8. PubMed ID: 12114409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary breast cancer phenotypes associated with propensity for central nervous system metastases.
    Tham YL; Sexton K; Kramer R; Hilsenbeck S; Elledge R
    Cancer; 2006 Aug; 107(4):696-704. PubMed ID: 16826579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical detection of breast cancer stem cells in hormone receptor-positive breast cancer and their role in response to endocrine therapy and clinical outcome.
    Hashimoto K; Shimizu C; Tsuda H; Saji S; Osaki A; Shigekawa T; Aogi K
    Oncology; 2012; 82(3):168-74. PubMed ID: 22433454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aldehyde dehydrogenase 1 expression is a predictor of poor prognosis in node-positive breast cancers: a long-term follow-up study.
    Yoshioka T; Umekita Y; Ohi Y; Souda M; Sagara Y; Sagara Y; Sagara Y; Rai Y; Tanimoto A
    Histopathology; 2011 Mar; 58(4):608-16. PubMed ID: 21371077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of ghrelin is correlated to a favorable outcome in invasive breast cancer.
    Grönberg M; Fjällskog ML; Jirström K; Janson ET
    Acta Oncol; 2012 Mar; 51(3):386-93. PubMed ID: 22067021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in PIK3CA mutation status are not associated with recurrence, metastatic disease or progression in endocrine-treated breast cancer.
    Arthur LM; Turnbull AK; Renshaw L; Keys J; Thomas JS; Wilson TR; Lackner MR; Sims AH; Dixon JM
    Breast Cancer Res Treat; 2014 Aug; 147(1):211-9. PubMed ID: 25104442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor topoisomerase II alpha status and response to anthracycline-based neoadjuvant chemotherapy in breast cancer.
    Nikolényi A; Sükösd F; Kaizer L; Csörgo E; Vörös A; Uhercsák G; Ormándi K; Lázár G; Thurzó L; Brodowicz T; Kahán Z
    Oncology; 2011; 80(3-4):269-77. PubMed ID: 21734419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of neoadjuvant chemotherapy on HER2/neu status in invasive breast cancer.
    Li P; Liu T; Wang Y; Shao S; Zhang W; Lv Y; Yi J; Wang Z
    Clin Breast Cancer; 2013 Feb; 13(1):53-60. PubMed ID: 23103368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy?
    McGuire KP; Toro-Burguete J; Dang H; Young J; Soran A; Zuley M; Bhargava R; Bonaventura M; Johnson R; Ahrendt G
    Ann Surg Oncol; 2011 Oct; 18(11):3149-54. PubMed ID: 21947592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of βIII-tubulin and survivin associated with drug resistance to docetaxel-based chemotherapy in advanced gastric cancer.
    Zheng WE; Chen H; Yuan SF; Wu LL; Zhang W; Sun HY; Chen WJ
    J BUON; 2012; 17(2):284-90. PubMed ID: 22740207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential TAG-72 epitope expression in breast cancer and lymph node metastases: a marker of a more aggressive phenotype.
    Galietta A; Pizzi C; Pettinato G; Limite G; Sgambato A; Lamberti M; Muraro R; Formisano C; Pensabene M; Bianco AR; Mariani-Costantini R; Contegiacomo A
    Oncol Rep; 2002; 9(1):135-40. PubMed ID: 11748471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor angiogenesis predicts clinical outcome of node-positive breast cancer patients treated with adjuvant hormone therapy or chemotherapy.
    Gasparini G; Barbareschi M; Boracchi P; Verderio P; Caffo O; Meli S; Dalla Palma P; Marubini E; Bevilacqua P
    Cancer J Sci Am; 1995; 1(2):131-41. PubMed ID: 9166466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paclitaxel as a first-line chemotherapy for Japanese women with advanced or recurrent breast cancer: a multi-institutional practice-based study by the Kyushu Breast Cancer Study Group (KBC-SG).
    Ishikawa M; Takamatsu Y; Mitsuyama S; Iwakuma N; Anan K; Umeda S; Tamura K
    Breast Cancer; 2010 Apr; 17(2):131-5. PubMed ID: 19472037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphorylated S6K1 is a possible marker for endocrine therapy resistance in hormone receptor-positive breast cancer.
    Kim EK; Kim HA; Koh JS; Kim MS; Kim KI; Lee JI; Moon NM; Ko E; Noh WC
    Breast Cancer Res Treat; 2011 Feb; 126(1):93-9. PubMed ID: 21184268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.